Jay Venkatesan
Known title: DirectorCIK: 0001413350
Jay Venkatesan's purchase track record
How the stock did after each of Jay Venkatesan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 4 since December 15, 2021
Stock higher 6 months later
0%
3 months: 25%
Median 6-month return
-32.7%
3 months: -18.5%
Beat the S&P 500
0%
median -19.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/22/2026 | SER | $1K | +45.0% | pending | — |
| 5/20/2022 | ELTX | $116K | -20.3% | -32.7% | +1.6% |
| 12/27/2021 | ELTX | $730K | -16.7% | -26.0% | -18.6% |
| 12/15/2021 | ELTX | $302K | -25.7% | -39.4% | -19.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SER | ▼ Sell | Other | 224,152 | $504K | 6/17/2026 | View on chart |
| SER | ▲ Buy | Open Market | 589 | $1K | 5/22/2026 | View on chart |
| SER | ▲ Buy | Grant | 7,553 | $15K | 3/31/2026 | View on chart |
| ELTX | ▼ Sell | Other | 50,000 | $500 | 11/26/2024 | View on chart |
| ELTX | ▲ Buy | Open Market | 11,313 | $14K | 5/25/2022 | View on chart |
| ELTX | ▲ Buy | Open Market | 32,200 | $40K | 5/24/2022 | View on chart |
| ELTX | ▲ Buy | Open Market | 50,000 | $62K | 5/20/2022 | View on chart |
| ELTX | ▲ Buy | Open Market | 210,337 | $560K | 12/28/2021 | View on chart |
| ELTX | ▲ Buy | Open Market | 66,907 | $171K | 12/27/2021 | View on chart |
| ELTX | ▲ Buy | Open Market | 3,527 | $9K | 12/20/2021 | View on chart |
| ELTX | ▲ Buy | Open Market | 13,742 | $35K | 12/17/2021 | View on chart |
| ELTX | ▲ Buy | Open Market | 27,883 | $71K | 12/16/2021 | View on chart |
| ELTX | ▲ Buy | Open Market | 77,604 | $187K | 12/15/2021 | View on chart |
| ELTX | ▼ Sell | Tax Withholding | 41,091 | $566K | 6/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target
Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.
ELTX presents Phase 2 data at ESMO Congress; B. Riley lowers target. Elicio Therapeutics disclosed that its late‑breaking Phase 2 AMPLIFY‑7P results have been selected for an oral presentation at the upcoming ESMO Congress 2026. The selection highlights ongoing clinical progress for the company's oncology program. Separately, B. Riley Securities kept its coverage on ELTX but reduced its price target to $8, reflecting a more cautious outlook.